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typ
wi
 study was carried out to determine 
 prevalence of microalbuminuria in 
e 2 diabetes and their relationship 
th risk factors.  
Materials & Methods: The study was performed 
at the outpatient diabetes clinic of Ardabil. We 
selected patients who had no evidence of pro-
teinuria in urinalysis and without abnormal se-
rum blood urea nitrogen (BUN) and creatinine. 
The patients were directed to provide timed 24 
hour urine samples for assessment of urinary al-
bumin twice in a period of 2-3 months. In the 
course of processing case histories the factors 
considered were duration of diabetes, hyperten-
sion history, smoking habits and number of vis-
its during the previous year. Laboratory investi-
gations included FBS, HbA1c, Tg, Cholesterol 
(Total, HDL, LDL), BUN and creatinine. 
Results: The prevalence of microalbuminuria 
(AER 31-299 mg/24 hr) was 30.5%. Significant 
differences were found with regard to duration 
of diabetes (p<0.01), hypertension (p<0.0001) and 
smoking habits (p<0.05) and the mean value of 
fasting plasma glucose (171±71 v.s 138±48, 
p=0.01) and triglyceride, (247±142 v.s 201±105, 
p=0.05). HbA1c levels (7.3±1.3 v.s 6.5±1.3, p=0.01) 
were significantly high in patients with microal-
buminuria as compared to patients with nor-
moalbuminuria, serum cholesterol; HDL and 
LDL showed no significant difference.  
Conclusion: Microalbuminuria was a major 
problem in our patients. Hypertension, smoking, 
poor glycemic control, duration of diabetes and 
serum levels of triglyceride were risk factors for 
development of microalbuminuria. 
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Introduction 
Diabetic nephropathy is a major health 
problem in diabetic patients. The natural his-
tory of diabetic nephropathy has generally 
been viewed as a descending path from nor-
moalbuminuria to end-stage renal disease 
(ESRD) through an intermediate stage 
marked by microalbuminuria and overt pro-
teinuria.1,2
It appears that the development of each 
stage of diabetic nephropathy is determined 
by somewhat different sets of risk factors. 
Whereas the level of glycemic control is most 
likely the dominant factor in the occurrence 
of micro-albuminuria,3 its progression 
through the more advanced stages is deter-
mined by such risk factors as hypertension, 
hypercholesterolemia and unidentified ge-
netic factors.4 In the course of diabetes melli-
tus, diabetic nephropathy develops in 30-40% 
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of patients with type 1 DM and in 10-20% of 
patients with type 2 DM, although the current 
incidence varies according to region and race.5,6
Two European clinical studies conducted 
on large populations of type 2 DM patients 
found that microalbuminuria occurred in 27% 
to 32.1% of individuals and macroalbuminu-
ria in 14% to 17.6%.7-8 Numerous other stud-
ies have reported the prevalence of microal-
buminuria in type 2 DM, which, however, 
varies widely (15-38%), because of the dif-
ferences in definition of microalbuminuria, 
and the methods of collecting urine speci-
men(time collection or random).9
The definition of microalbuminuria (MA) 
is somewhat different according to various 
authors; it was defined as urine albumin ex-
cretion rate (UAER) of more than 30 mg/min 
by Viberti et al.10 more than 15 mg/ min by 
Mogensen and Christinen,11 or more than 40 
mg/L by Parving et al.12 Kaplan defined it as 
UAER of 30-300 mg/24 hours= 20-200 
mg/min.13 In this study microalbuminuria 
was defined as UAER of 30-300 mg/24hr and 
macroalbuminuria as more than 300 mg/24 
hours. In this study we used timed urine col-
lection, 24 hours. There are various methods 
of measurement of urine albumin-excretion 
rate (UAER), including RUS first morning 
urine, and a timed urine collection (24 hours, 
8 hours, overnight, etc.). A timed urine col-
lection (24 hours or overnight) is the most 
sensitive assay for measuring UAER, how-
ever, a RUS is more practical and convenient 
than the timed urine collection; a new albu-
min assay using high-performance liquid 
chromatography (HPLC) has also been devel-
oped.14-17
A prevalence of 16-35% has been reported 
in studies from Iran with similar methods of 
collection.18-20 Although there have been 
various studies of screening tests for diabetic 
nephropathy, little data exists regarding the 
prevalence of the MA in Iran. This study was 
carried out to determine the prevalence and 
the associated features of MA among sub-
jects attending the Ardabil diabetes clinic. 
Materials and Methods 
This study was performed at the outpatient 
diabetic clinic in Bouali-hospital in Ardabil, 
between May 2003 and August 2004. We se-
lected 125 patients who had no evidence of 
protenuria in urine analysis and had abnormal 
BUN and creatinine (BUN ≤ 25, Cr≤ 1.3 
mg/dl). At first a urine analysis (UA) was 
done and if this was positive for proteinuria, 
in order to rule out etiologies like infections, 
such as UTI, hypertension, CHF, another UA 
would be done after 2 weeks, and if the sec-
ond specimen was negative for proteinuria, 
the patient would be included in the study. 
UA was not carried out after exercise and in 
women during menstruation. 
The patients were instructed to give timed 
24 hour urine samples for urinary albumin, 
which was measured twice, by immunotur-
bometric assay using a Randox kit by Hitachi 
902 analyzer (a product of Rosch & Hitachi 
Inc), within a period of 2-3 months. If albu-
min excretion rate (UAER) was between 30-
300 mg/24hr in both samples, the patient was 
considered microalbuminuric. If it was posi-
tive in only one sample, urine collection was 
repeated for the third time. The total length of 
followup was 6-9 months. Subjects were di-
vided into normoalbuminuric (UAER ≤ 30), 
microalbuminuric (UAER as 31-299) and 
macroalbuminuric (UAER ≥ 300 mg/24hr). 
In the course of processing case histories, 
the factors considered were the duration of 
DM, hypertension history, smoking habits 
and the number of visits during the previous 
year. Hypertension was defined as having 
blood pressure ≥ 140/90; the mean of 2 blood 
pressure readings was considered, or cur-
rently undergoing anti-hypertensive treat-
ment. Body mass index (BMI) was calculated 
as weight kg/height (m)2: BMI 18- 24.9 was 
considered normal, 25-29.9 overweight, and 
≥ 30 as obese.  
Laboratory findings included: fasting 
plasma glucose, HbA1c, serum triglyceride, 
total cholesterol (LDL, HDL), BUN and 
creatinine. 
International Journal of Endocrinology and Metabolism  
 www.SID.ir
Ar
ch
ive
 of 
SID
10 M. Iranparvar Alamdari et al.  
 
HbA1c was measured by HbGold analyzer 
(Drew company), which uses slow pressure 
conjunction exchange chromatography in 
conjunction with gradient elution to separate 
human haemglobin subtypes and variants 
from haemolysed whole blood. Glucose, 
Chol, TC, HDL, LDL (direct assay) were 
measured using the enzymatic assay (Pars 
Azemon kit and Hitachi 902 Autoanalyser 
system).  
Results were expressed as mean ± SD. X2 
test and ANOVA were used for comparisons 
between the groups. A p-value less than 0.05 
was considered to be significant.  
 
Results  
This study was performed in 125 DM type 
2 outpatients; 31 males, 94 females aged 30-
81 years (mean age 55.7±10.9 yrs). Of the 
125, 83 patients (66%) were normoalbu-
minuic (NA), 39 patients (30.5%) were mi-
croalbuminuic (MA) and 3 patients (2.3%) 
had macroalbuminuria. Baseline characteris-
tics of the patients are shown in table 1. Du-
ration of DM had been calculated in average 
years from data of DM diagnosis. It is clear 
that many of the patients had been dignosed 
after the actual onset of type 2 DM.  
Significant differences were found in the 
NA and MA groups regarding duration of 
diabetes, hypertension and smoking habits 
(Table1). 
Table 2 summarizes the laboratory parame-
ters. The mean value of fasting plasma glu-
cose and HbA1c levels were significantly 
higher in patients with MA as compared to 
patients with NA respectively (p<0.003 and 
p<0.005). Serum triglyceride levels in both 
groups exceeded the upper limits of normal 
(<150mg/dl) and these values in MA patients 
were significantly higher than those of NA 
patients (p<0.04).  
Serum cholesterol, HDL, LDL cholesterol 
levels in both groups were within the normal 
limits; no significant differences between 
these groups could be detected. 
 
 
 
Table 1. Baseline features of patients in relation to the rate of albuminuria 
 
 NA (n=83) MA (n= 39) P 
Age 54.8±11.8 57.4±8.4 NS 
Duration of Diagnosis of DM(yr) 7.1±4.3 9.7±5.7 0.005 
Smoking habits(S/NS) 19/64 16/23 0.04 
Hypertension(H/N) 33/52 31/8 0.0001 
BMI (Kg/m2) 27.9±4.1 28.3±4.8 NS 
NA- normoalbuminuria, MA- microalbuminuria, D-diabetes mellitus, H-hypertensive,  
N-normal blood pressure, S-smoker, NS-nonsmoker. 
 
 
Table 2. Laboratory findings among DM type 2 patients 
 
 NA (n=83) MA (n=39) P 
Fasting plasma glucose (mg/dL) 138±48.5 171.5±71.5 0.003 
HbA1c (%) 6.5±1.3 7.3±1.3 0.005 
Serum triglyceride (mg/dL) 201±105 247±142 0.04 
Serum cholesterol (mg/dL) 190.8±81 187±40 NS 
Serum HDL- cholesterol (mg/dL) 44.9±12 47.6±26.7 NS 
Serum LDL-cholesterol (mg/dL) 117±30 108±23 NS 
NA- normoalbuminuria, MA- microalbuminuria 
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Discussion 
Numerous studies have reported the preva-
lence of MA in type-2 DM patients, which, 
however, varies widely (15-38%). The preva-
lence of MA in our patients with type-2 dia-
betes mellitus was 30.5 % which is similar to 
results of other studies.7,8,20
Our results produced evidence of signifi-
cant difference between duration of diabetes 
in NA and MA groups (p<0.005). Although, 
some authors have reported a strong correla-
tion between the severity of UAE and dura-
tion of diabetes in type-2 diabetes,21,22 other 
studies produced no such evidence.23
High prevalence of hypertension was found 
in the MA group (79.5%) and was correlated 
with it (p<0.001). Bruno et al have reported 
high blood pressure levels among MA pa-
tients.8 Other studies also have reported simi-
lar results.18-20-24  
The high average values of BMI in our pa-
tients with NA, MA, indicated that the major-
ity of them were overweight. Some studies 
claim obesity to be a potential risk factor for 
albuminuria25 while others postulate that it 
has little effect on the development of 
MA.8,23  
We also found more smokers in the MA 
group (p<0.04). Some studies revealed, that 
in type-2 DM, the risk of albuminuria is 
higher in smokers and former smokers, than 
in the non-smokers.8,25 The role of metabolic 
control in the development of diabetic neph-
ropathy has been justified by several studies, 
the most convincing being the DCCT study.26 
Although hyperglycemia has been shown to 
be a risk factor for microalbuminuria and 
overt proteinuria in patients with type-2 
DM,21 others have failed to confirm this as-
sociation.23,27 Our findings showed insuffi-
cient glycemic control among cases of the 
MA group in comparison with the NA group. 
The increase in triglyceride levels was even 
more marked in both groups and a significant 
difference was found between the two groups 
(p<0.04).  
Also serum cholesterol level, HDL and 
LDL-cholesterol were within the normal 
range in both groups and no significant dif-
ferences were found between them. Because 
our patient were currently taking statins we 
did not find any relation between serum cho-
lesterol level and MA in this study. The role 
of hyperlipidemia in the development of dia-
betic nephropathy has been described in sev-
eral studies. In the vast majority of the stud-
ies, cholesterol and triglycerides showed a 
positive correlation with the degree of albu-
minuria, while HDL cholesterol was found to 
have a negative correlation with it;8,23,28 while 
some of the studies produced no such result, 
a high prevalence of MA was detected in 
type2 DM patients.  
 
Conclusion 
According to the findings of this study hy-
pertension, smoking, poor glycemic control, 
duration of diabetes and serum levels of 
triglyceride were found to be risk factors for 
development of MA. 
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